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Introduction. This is the case of a young male patient who presented to his family physician with atypical left foot pain, which
was extremely resistant to analgesia and caused significant disability. Despite extensive investigations, the cause of his pain was
not identified until 18 months after his initial symptoms, when the oﬃcial diagnosis of malignant peripheral nerve sheath tumour
(MPNST) was made. Detailed review of the patient’s past history established the diagnosis of type I neurofibromatosis (NF-
1), previously undetected. Discussion. NF-1 is an autosomal dominant genetic disorder caused by loss of function mutations of
the NF1 gene in chromosome 17. Patients with this condition are at increased risk for developing MPNSTs which, however, are
treatable only in early stages. Conclusion. Althoughmonitoring NF-1 patients for the development ofMPNSTs is common practice,
the index of clinical suspicion in patients without an established NF-1 diagnosis is low. Any atypical pain in young adults should
raise the possibility of this malignancy, and this case illustrates the fact that MPNSTs can be the first manifestation of NF-1 in
patients previously undiagnosed with the disease.
1. Case Report
A 24-year-old male smoker presented to his GP with a 6-
month history of right foot pain extending from the base of
the first toe to the plantar surface of the foot. The pain was
fluctuating in severity, did not correlate with specific activ-
ities, and was only partially relieved with common analgesics.
The patient’s work involved prolonged standing and heavy
lifting. He had had bilateral pes planus and valgus heels dur-
ing his childhood but had been asymptomatic for several
years. Two abdominal nodules had been excised by a derma-
tologist two years prior to the onset of his presenting com-
plaint. The histopathology report confirmed they were a fi-
broma and a leiomyoma of no particular clinical signifi-
cance. Apart from a few other minor injuries, his past medi-
cal and surgical history was otherwise unremarkable.
The pain was attributed to the patient’s previous pes pla-
nus deformity and was treated conservatively with common
analgesia by the GP. Over the next three months the pain did
not resolve and the patient was referred to the local ortho-
pedics outpatient clinic. Extensive X-ray studies and blood
tests including inflammatory and immunological markers
were all normal, and the patient was referred to Orthotics
for foot arch support.
Despite the arch support, the pain progressively wors-
ened over the next 6 months. A foot MRI revealed mild, early
degenerative 1st MTP joint changes with a small amount of
fusion, but no other abnormalities. The diagnosis of reflex
sympathetic dystrophy was also considered and supported by
the findings of a radionuclide isotope scan. Although rocker
soles and stronger analgesia (including oral morphine) were
suggested, these failed to control the symptoms. Although
this was followed by physiotherapy and multiple guanethi-
dine blocks, symptoms remained uncontrolled and caused
significant disability 18 months after the patient’s first GP
visit.
In the following weeks the patient developed progressive
weight loss, fatigue, and muscle wasting below the knee. He
noticed for the first time a firm round mass (approximately
15 cm) on the lower aspect of the posterior thigh. He was re-
ferred back to Orthopaedics and an urgent MRI confirmed
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Figure 1: UrgentMRI of the right lower limb; T1 weighted (left), T2
weighted (right). A large (approx. 15 cm), oval, smoothly defined
heterogenous mass with a large necrotic centre is clearly visible be-
hind the lower femur (white arrows). There is also an area of al-
tered signal within the femur itself involving the condyle, suggest-
ive of bony metastasis (white arrowheads). The likely diagnosis is
malignant peripheral nerve sheath tumor (MPNST) with a diﬀeren-
tial diagnosis of lymphoma or other soft tissue sarcoma. The charac-
ter and distribution of the pain could signify a sciatic nerve origin.
an oval, smoothly defined heterogenous mass in addition
to signal changes in both right and left femurs, most likely
representing metastatic foci (Figure 1).
The appearances were most suggestive of metastatic
malignant peripheral nerve sheath tumour (MPNST), and
the patient was urgently referred to Oncology. Chest CT and
whole-body MRI revealed the presence of multiple lung and
bonemetastases, consistent with stage IVbmalignant disease.
Predisposing factors for this rare malignancy including NF-
1 were considered. A detailed clinical examination revealed
freckling of the right axillary region. In addition, the histol-
ogy slides from the patient’s abdominal skin nodule biopsy
were reexamined by a specialist. The initial fibroma diagnosis
was inconsistent with histopathological findings, which were
more in keeping with an intraneural neurofibroma, part of a
plexiform neurofibroma.
Based on the National Institute of Health (NIH) diagnos-
tic criteria, the patient was diagnosed with neurofibromatosis
type I [1]. The patient was started on palliative chemotherapy
with doxorubicin, but unfortunately died 4 months later,
almost 24 months from his initial complaint.
2. Discussion
Type I neurofibromatosis (NF-1) is a common autosomal
dominant neurocutaneous disorder, characterized by multi-
ple cafe´ au lait spots, axillary and inguinal freckling, multiple
cutaneous neurofibromas, and iris Lisch nodules [2]. Clinical
diagnosis of NF-1 is made using the 1988 NIH diagnostic
criteria presented in Table 1.
Table 1: National Institute of Health diagnostic criteria for
neurofibromatosis type I [1]. The criteria are met in an individual
if two or more of the features listed are present.
Diagnosis of neurofibromatosis type 1 (NF1)
(1) Six or more cafe´ au lait macules >5mm in greatest diameter in
prepubertal individuals and >15mm in greatest diameter in
postpubertal individuals
(2) Two or more neurofibromas of any type or one plexiform
neurofibroma
(3) Freckling in the axillary or inguinal regions (Crowe’s sign)
(4) Optic glioma
(5) Two or more Lisch nodules (iris hamartomas)
(6) A distinctive osseous lesion such as sphenoid dysplasia or
thinning of long bone cortex with or without pseudoarthrosis
(7) A first-degree relative (parent, sibling, or oﬀspring) with NF1
by the above criteria
NF-1 is caused by loss of function mutations in the
NF1 gene in 17q11.2. This leads to defective production of
neurofibromin, a guanosine triphosphatase-activating
protein that helps maintain the protooncogene Ras in its
inactive form [3]. Loss of neurofibromin predisposes to in-
creased tumorigenesis, and malignant disease can appear in
either childhood or adulthood, with malignant peripheral
nerve sheath tumours (MPNSTs) being most common [4].
Several pathways are thought to be involved in the develop-
ment of tumours associated with NF1: rat sarcoma viral
oncogene homologue (RAS)-mitogen-activated protein kin-
ase (MAPK), mammalian target of rapamycin (mTOR), and
P21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) [5, 6].
NF-1 patients have a lifetime risk of 8–13% to develop
MPNSTs, which are the leading cause of NF1-related mor-
tality. In current clinical practice the diagnosis of MPNST
should always be considered in NF-1 patients, especially
those with persistent pain (that lasts over 1month or disturbs
sleep), new neurological deficits, or alteration in the char-
acteristics of a known neurofibroma [7]. Surgical resection
is the mainstay of treatment; however, because of increased
metastatic potential and resistance to chemotherapy and
radiation the prognosis is poor. Five-year survival rates still
only reach 20–50%, despite latest eﬀorts to identify potential
molecular targets [8].
MPNSTs should be included in the diﬀerential diagnosis
of persistent or atypical pain in a young adult. Although
rare, these malignancies are commonly associated with NF-1
and can be the first manifestation of the disease, as this case
illustrates. Early diagnosis is paramount as survival rates are
extremely poor in advanced stages of the malignancy.
3. Conclusion
MPNSTs can present with atypical symptoms in the young
adult population and are often diﬃcult to diagnose in previ-
ously healthy individuals. Unexplained pain that causes sig-
nificant disability despite strong analgesia should be thor-
oughly investigated until serious underlying malignancy is
excluded. Although not exclusively associated with NF-1,
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detection of an MPNST should prompt the physician to con-
sider the diagnosis and seek specialist help.
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